Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
GSK PLC Sponsored ADR (GSK) - free report >>
Johnson & Johnson (JNJ) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK PLC Sponsored ADR (GSK) - free report >>
Johnson & Johnson (JNJ) - free report >>
Image: Bigstock
Inovio Expands Enrollment in Ebola Vaccine Phase I Study
Late last week, Inovio Pharmaceuticals, Inc. (INO - Free Report) announced that it is expanding the enrollment in a phase I study evaluating its Ebola DNA vaccine, INO-4212. The company is enrolling 125 patients in the second stage of a phase I study on INO-4212 and will evaluate immune response characteristics generated with fewer intradermal administrations, lower doses, and with or without its DNA-based IL-12 immune activator.
The study will also help characterize and identify in humans the most optimal immunization regimen using intradermal (skin) delivery of its preventive Ebola DNA vaccine.
The decision to expand study enrollment came after positive initial safety and immune response data was received from the first set of 75 healthy volunteers. The initial 75-patient stage of the study evaluated INO-4212 in muscle and skin in five study arms in two and three doses, one including Inovio’s DNA-based IL-12 immune activator.
Inovio plans to meet with regulators regarding the path forward for INO-4212 following the close of this study, which it anticipates early next year.
INOVIO PHARMAC Price
INOVIO PHARMAC Price | INOVIO PHARMAC Quote
We note that the company was awarded a $45 million grant by the Defense Advanced Research Projects Agency in 2015 to lead a collaborative team for the development of multiple treatment and prevention approaches against Ebola. The Inovio-led consortium is taking a multi-faceted approach to develop treatments for the prevention of Ebola.
And it’s not just Inovio taking action to curb this lethal disease in the absence of an approved vaccine or treatment. Companies like GlaxoSmithKline plc (GSK - Free Report) , Johnson & Johnson (JNJ - Free Report) and Merck & Co., Inc. (MRK - Free Report) among others are also developing Ebola vaccines.
In fact, Merck’s Ebola Zaire vaccine candidate known as V920 received Breakthrough Therapy status from the FDA while the European Medicines Agency provided the candidate PRIME (PRIority MEdicines) status last month.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>